Author: admin

DelveInsight’s “Helicobacter pylori Infection Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Helicobacter pylori Infection, historical and forecasted epidemiology as well as the Helicobacter pylori Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Helicobacter pylori Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Helicobacter pylori Infection Market Forecast

Some of the key facts of the Helicobacter pylori Infection Market Report:

• The Helicobacter pylori Infection market size was valued approximately USD 2,672 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In November 2024, TenNor Therapeutics has revealed that its antibiotic candidate, rifasutenizol, has successfully met all primary endpoints in a Phase III trial, outperforming the current standard of care (SoC). The multicenter, randomized, double-blind, controlled trial (NCT05857163) demonstrated that rifasutenizol triple therapy achieved an eradication rate of over 90%, surpassing the effectiveness of bismuth-containing quadruple therapy (BQT) in treating Helicobacter pylori (H. pylori) infection, a prevalent bacterial infection of the stomach often responsible for stomach ulcers.

• The market size for Helicobacter pylori infection in the US was around USD 1,064.8 million in 2022, and it is expected to grow driven by rising disease awareness and the introduction of emerging therapies.

• The total market size for the EU4 and the UK was estimated at approximately USD 1,028.3 million in 2022, accounting for nearly 38% of the total market revenue across the 7MM.

• According to the analysis, in the US, clarithromycin-based triple therapy held the second-largest market share among the currently used therapies, generating approximately USD 351.0 million in revenue in 2022.

• In 2022, Japan recorded a revenue of approximately USD 579.4 million, representing the second-largest market size for Helicobacter pylori Infection among the 7MM, with significant growth expected by 2034.

• In 2022, the total diagnosed prevalent cases of Helicobacter pylori infection across the 7MM were estimated to be around 321,217,226, with the US contributing approximately 37%, EU4 and the UK accounting for about 43%, and Japan representing around 20% of the total diagnosed cases.

• In 2022, the US recorded approximately 118,650,370 total diagnosed prevalent cases of Helicobacter pylori infection, which are anticipated to rise throughout the study period as disease awareness and diagnosis improve.

• According to the analysis, EU4 and the UK had approximately 138,397,508 diagnosed prevalent cases of Helicobacter pylori infection in 2022. These figures are projected to change throughout the study period (2020–2034).

• Key Helicobacter pylori Infection Companies: RedHill Biopharma, Phathom Pharmaceuticals, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, AbbVie, TenNor Therapeutics, Nexbiome therapeutics, Cinclus Pharma, Elpen Pharmaceutical, TenNor Therapeutics, Phathom Pharmaceuticals, HK inno.N Corporation, Deva Holding A.S., Meridian Bioscience, Inc., Takeda, RedHill Biopharma, Janssen Cilag Pharmaceutica, Takeda, Il-Yang Pharm, Forest Laboratories, and others

• Key Helicobacter pylori Infection Therapies: TALICIA (RHB-105), VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, TAKECAB (vonoprazan), PYLERA, Rifasutenizole (TNP-2198), BGA-1901, Linaprazan glurate, Esomeprazole, TNP-2198, Vonoprazan, Tegoprazan, Levofloxacin, Lansoprazole (Lanton), Vonoprazan, RHB-105, rabeprazole sodium, TAK-438, Ilaprazole + Amoxicillin, Omeprazole, amoxicillin, clarithromycin, and others

• The Helicobacter pylori Infection epidemiology based on gender analyzed that there is a higher male preponderance in the prevalence of H. pylori infection

• The Helicobacter pylori Infection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Helicobacter pylori Infection pipeline products will significantly revolutionize the Helicobacter pylori Infection market dynamics.

Helicobacter pylori Infection Overview

Helicobacter pylori (H. pylori) infection is a condition in which the stomach is infected with the bacterium Helicobacter pylori. This bacterium is a common cause of stomach ulcers and can also lead to other gastrointestinal issues.

Get a Free sample for the Helicobacter pylori Infection Market Report:

https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Helicobacter pylori Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Helicobacter pylori Infection Epidemiology Segmentation:

The Helicobacter pylori Infection market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of H. pyloriGender-specific Diagnosed Prevalent

• Cases of H. pylori infection in the 7MM infection in the 7MM

• Age-specific Diagnosed Prevalent Cases of H. pylori infection in the 7MM

Download the report to understand which factors are driving Helicobacter pylori Infection epidemiology trends @ Helicobacter pylori Infection Epidemiology Forecast

Helicobacter pylori Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Helicobacter pylori Infection market or expected to get launched during the study period. The analysis covers Helicobacter pylori Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Helicobacter pylori Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Helicobacter pylori Infection Therapies and Key Companies

• TALICIA (RHB-105): RedHill Biopharma

• VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK: Phathom Pharmaceuticals

• TAKECAB (vonoprazan): Takeda Pharmaceutical/Otsuka Pharmaceutical

• PYLERA: Juvisé Pharmaceuticals/AbbVie

• Rifasutenizole (TNP-2198): TenNor Therapeutics

• BGA-1901: Nexbiome therapeutics

• Linaprazan glurate: Cinclus Pharma

• Esomeprazole: Elpen Pharmaceutical

• TNP-2198: TenNor Therapeutics

• Vonoprazan: Phathom Pharmaceuticals

• Tegoprazan: HK inno.N Corporation

• Levofloxacin: Deva Holding A.S.

• Lansoprazole (Lanton): Meridian Bioscience, Inc.

• Vonoprazan: Takeda

• RHB-105: RedHill Biopharma

• rabeprazole sodium: Janssen Cilag Pharmaceutica

• TAK-438: Takeda

• Ilaprazole + Amoxicillin: Il-Yang Pharm

• Omeprazole, amoxicillin, clarithromycin: Forest Laboratories

Discover more about therapies set to grab major Helicobacter pylori Infection market share @ Helicobacter pylori Infection Treatment Market

Helicobacter pylori Infection Market Strengths

• High prevalence of H. pylori and increasing awareness about the infections among people will help drive the H. pylori market.

• Several regimens such as bismuth, sequential therapy, concomitant therapy, and others have become available which will help improve the treatment and overcome the limitations of first-line Clarithromycin-based triple therapy

Helicobacter pylori Infection Market Opportunities

• Development of novel therapeutic approaches considering the increasing resistance rates despite the use of combined broad-spectrum antibiotics, bismuth, and acid inhibitors.

• To adapt clinical trials with a focus on achieving high cure rates to ensure antimicrobial stewardship

Scope of the Helicobacter pylori Infection Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Helicobacter pylori Infection Companies: RedHill Biopharma, Phathom Pharmaceuticals, Takeda Pharmaceutical, Otsuka Pharmaceutical, Juvisé Pharmaceuticals, AbbVie, TenNor Therapeutics, Nexbiome therapeutics, Cinclus Pharma, Elpen Pharmaceutical, TenNor Therapeutics, Phathom Pharmaceuticals, HK inno.N Corporation, Deva Holding A.S., Meridian Bioscience, Inc., Takeda, RedHill Biopharma, Janssen Cilag Pharmaceutica, Takeda, Il-Yang Pharm, Forest Laboratories, and others

• Key Helicobacter pylori Infection Therapies: TALICIA (RHB-105), VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, TAKECAB (vonoprazan), PYLERA, Rifasutenizole (TNP-2198), BGA-1901, Linaprazan glurate, Esomeprazole, TNP-2198, Vonoprazan, Tegoprazan, Levofloxacin, Lansoprazole (Lanton), Vonoprazan, RHB-105, rabeprazole sodium, TAK-438, Ilaprazole + Amoxicillin, Omeprazole, amoxicillin, clarithromycin, and others

• Helicobacter pylori Infection Therapeutic Assessment: Helicobacter pylori Infection current marketed and Helicobacter pylori Infection emerging therapies

• Helicobacter pylori Infection Market Dynamics: Helicobacter pylori Infection market drivers and Helicobacter pylori Infection market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Helicobacter pylori Infection Unmet Needs, KOL’s views, Analyst’s views, Helicobacter pylori Infection Market Access and Reimbursement

To know more about Helicobacter pylori Infection companies working in the treatment market, visit @ Helicobacter pylori Infection Clinical Trials and Therapeutic Assessment

Table of Contents

1. Helicobacter pylori Infection Market Report Introduction

2. Executive Summary for Helicobacter pylori Infection

3. SWOT analysis of Helicobacter pylori Infection

4. Helicobacter pylori Infection Patient Share (%) Overview at a Glance

5. Helicobacter pylori Infection Market Overview at a Glance

6. Helicobacter pylori Infection Disease Background and Overview

7. Helicobacter pylori Infection Epidemiology and Patient Population

8. Country-Specific Patient Population of Helicobacter pylori Infection

9. Helicobacter pylori Infection Current Treatment and Medical Practices

10. Helicobacter pylori Infection Unmet Needs

11. Helicobacter pylori Infection Emerging Therapies

12. Helicobacter pylori Infection Market Outlook

13. Country-Wise Helicobacter pylori Infection Market Analysis (2020–2034)

14. Helicobacter pylori Infection Market Access and Reimbursement of Therapies

15. Helicobacter pylori Infection Market Drivers

16. Helicobacter pylori Infection Market Barriers

17. Helicobacter pylori Infection Appendix

18. Helicobacter pylori Infection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Helicobacter pylori Infection Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | RedHill Biopharma, Phathom Pharma, Takeda Pharma, Otsuka Pharma, Juvisé Pharma, AbbVie, TenNor

The Spasticity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spasticity pipeline products will significantly revolutionize the Spasticity market dynamics.

DelveInsight’s “Spasticity Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Spasticity, historical and forecasted epidemiology as well as the Spasticity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spasticity market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Spasticity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spasticity Market Insights

Some of the key facts of the Spasticity Market Report:

• The Spasticity market size was valued approximately USD 904 million in 2021 is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In December 2024, Health Canada approved XEOMIN® (incobotulinumtoxinA) for the treatment of post-stroke lower limb spasticity in adults. This marks a key advancement in Canadian healthcare, expanding the therapeutic reach of XEOMIN and allowing clinicians to treat both upper and lower limb spasticity in a single patient, using up to a total of 600 units. This label extension reinforces XEOMIN’s essential role in neurological rehabilitation—from enhancing mobility to alleviating pain. Each year, over 109,000 Canadians suffer strokes, and many survivors develop spasticity within a year. This latest approval is XEOMIN’s sixth indication in Canada, alongside uses such as cervical dystonia and chronic sialorrhea.

• In October 2024, Saol Therapeutics, a privately-owned clinical-stage pharmaceutical firm, has reported positive topline results from its SL-1002 RAISE Limb Spasticity Trial (NCT05311215). These findings were recently shared during the Spasticity X Symposium held in Houston, Texas.

• In January 2024, Ipsen (Euronext: IPN; ADR: IPSEY) recently revealed top-line results from its real-world AboLiSh study (NCT04050527), presented at the 7th International TOXINS Conference in Berlin, Germany. The study assessed the use and effectiveness of Dysport® (abobotulinumtoxinA) in individuals with lower-limb spasticity, highlighting that injection guidance techniques notably enhance patient outcomes and goal achievement.

• Spasticity is one of the most common symptoms of multiple sclerosis (MS) and is defined as muscle stiffness that is frequently generalized and that causes more or less continuous rigidity

• There were approximately 2,328,000 prevalent cases of Spasticity in the United States in 2021

• According to the analysis, DelveInsight estimated approximately 415,000 prevalent cases of Spasticity in Germany in 2021

• Key Spasticity Companies: Jazz Pharmaceuticals, Revance Therapeutics, Ipsen, and others

• Key Spasticity Therapies: Nabiximols, DAXI, IPN10200, and others

• The Spasticity epidemiology based on gender analyzed that Males are more at risk of developing Spasticity in comparison to the females

Spasticity Overview

Spasticity is defined as “sensorimotor disorder characterized by a velocity-dependent increase in tonic stretch reflexes with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex” or from an upper motor neuron lesion (UMN),presenting as an intermittent or sustained involuntary activations of muscles. The region and the extent of impairment depend on the area of the brain or spinal cord that has been damaged. It can occur in the upper and/or lower limbs

Get a Free sample for the Spasticity Market Report:

https://www.delveinsight.com/report-store/spasticity-market

Spasticity Market

The dynamics of the Spasticity market are anticipated to change in the coming years owing to the expected launch of emerging therapies such and others during the forecasted period 2019-2032.

“The emerging therapies for the treatment of Spasticity include Nabiximols, DAXI and others. Approval of these therapies will provide new and different treatment options to the patients and will hence drive the market.”

Spasticity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Spasticity Epidemiology Segmentation:

The Spasticity market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Spasticity

• Prevalent Cases of Spasticity by severity

• Gender-specific Prevalence of Spasticity

• Diagnosed Cases of Episodic and Chronic Spasticity

Download the report to understand which factors are driving Spasticity epidemiology trends @ Spasticity Epidemiological Insights

Spasticity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spasticity market or expected to get launched during the study period. The analysis covers Spasticity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spasticity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Spasticity Therapies and Key Companies

• Nabiximols: Jazz Pharmaceuticals

• DAXI: Revance Therapeutics

• IPN10200: Ipsen

To know more about Spasticity treatment, visit @ Spasticity Medications

Scope of the Spasticity Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Spasticity Companies: Jazz Pharmaceuticals, Revance Therapeutics, Ipsen, and others

• Key Spasticity Therapies: Nabiximols, DAXI, IPN10200, and others

• Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies

• Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Spasticity Unmet Needs, KOL’s views, Analyst’s views, Spasticity Market Access and Reimbursement

Discover more about therapies set to grab major Spasticity market share @ Spasticity Treatment Landscape

Table of Contents

1. Spasticity Market Report Introduction

2. Executive Summary for Spasticity

3. SWOT analysis of Spasticity

4. Spasticity Patient Share (%) Overview at a Glance

5. Spasticity Market Overview at a Glance

6. Spasticity Disease Background and Overview

7. Spasticity Epidemiology and Patient Population

8. Country-Specific Patient Population of Spasticity

9. Spasticity Current Treatment and Medical Practices

10. Spasticity Unmet Needs

11. Spasticity Emerging Therapies

12. Spasticity Market Outlook

13. Country-Wise Spasticity Market Analysis (2019–2032)

14. Spasticity Market Access and Reimbursement of Therapies

15. Spasticity Market Drivers

16. Spasticity Market Barriers

17. Spasticity Appendix

18. Spasticity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spasticity Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | Jazz Pharmaceuticals, Revance Therapeutics, Ipsen

DelveInsight’s “Menkes Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Menkes Disease, historical and forecasted epidemiology as well as the Menkes Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Menkes Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Menkes Disease Market Forecast

Some of the key facts of the Menkes Disease Market Report:

• The Menkes Disease market size was valued ~8 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In January 2025, Sentynl Therapeutics, Inc., a U.S.-based biopharma company fully owned by Zydus Lifesciences Ltd. (Zydus Group), along with Fortress Biotech, Inc. (Nasdaq: FBIO), announced that the U.S. FDA has accepted and granted Priority Review to Sentynl’s New Drug Application (NDA) for CUTX-101, a treatment candidate for Menkes disease. This rare, X-linked recessive pediatric disorder results from mutations in the ATP7A copper transporter gene. Estimates place its prevalence between 1 in 34,810 and 1 in 8,664 live male births.

• In January 2025, Fortress Biotech, Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CUTX-101 (Copper Histidinate). The therapy is intended for the treatment of Menkes disease, a rare X-linked recessive pediatric condition caused by mutations in the ATP7A copper transporter gene.

• The Standard of Care accounted for the entire market, which was valued at approximately USD 7.9 million in 2023 across the 7MM.

• According to our assessment, there were approximately 177 diagnosed prevalent cases of Menkes Disease in the 7MM in 2023, with expectations for these numbers to rise by 2034. The US had the highest number of cases.

• Among European countries in 2023, France had the highest diagnosed prevalent cases of Menkes Disease at 26%, followed by Germany and the UK, each with 24%. Conversely, Spain had the lowest diagnosed prevalence, accounting for 11%.

• In 2023, the US represented the largest share of diagnosed Menkes disease cases in the 7MM, with 54%, followed by Japan, which accounted for approximately 11%. Among European countries, France had the highest number of cases, representing about 9% of the total 7MM cases.

• In 2023, France held the largest market share in the EU4 and UK region with 27%, while Spain had the smallest share at 12%.

• The 7MM treatment market currently lacks an approved targeted therapy for Menkes Disease. However, with the anticipated launch of CUTX-101 by 2025, the market is expected to see significant growth.

• Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others

• Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others

• The Menkes Disease epidemiology based on gender analyzed that Menkes Disease usually affects male neonates through unaffected carrier women. It may occurs in females, related to unusual genetic circumstances

• The Menkes Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Menkes Disease pipeline products will significantly revolutionize the Menkes Disease market dynamics.

Menkes Disease Overview

Menkes disease (MD) is an X-linked inherited fatal infantile neurodegenerative condition. Mutations in the ATP7A gene, which is in charge of carrying copper throughout the body, result in this inherited X-linked recessive illness.

Get a Free sample for the Menkes Disease Market Report:

https://www.delveinsight.com/report-store/menkes-disease-market

Menkes Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Menkes Disease Epidemiology Segmentation:

The Menkes Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Menkes Disease

• Prevalent Cases of Menkes Disease by severity

• Gender-specific Prevalence of Menkes Disease

• Diagnosed Cases of Episodic and Chronic Menkes Disease

Download the report to understand which factors are driving Menkes Disease epidemiology trends @ Menkes Disease Epidemiology Forecast

Menkes Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Menkes Disease market or expected to get launched during the study period. The analysis covers Menkes Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Menkes Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Menkes Disease Therapies and Key Companies

• Copper Histidinate: Cyprium Therapeutics, Inc.

• CUTX-101: Cyprium Therapeutics and Sentynl Therapeutics

Discover more about therapies set to grab major Menkes Disease market share @ Menkes Disease Treatment Market

Menkes Disease Market Drivers

• Submission of NDA of CUTX-101

• Increasing awareness among families who have a history of Menkes

• Parents of affected babies understand the rarity of the disease and allow their children to be a part of the trial

• Ongoing development of screening techniques

• Ongoing development of gene therapy

Menkes Disease Market Barriers

• Clinical challenges in the early diagnosis of disease

• Inability to trace the carrier mother

• Insufficient number of studies to estimate the exact number of Menkes patients

• Insufficient number of researches for the treatment of Menkes disease

Scope of the Menkes Disease Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Menkes Disease Companies: Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc., and others

• Key Menkes Disease Therapies: CUTX-101, Copper Histidinate, and others

• Menkes Disease Therapeutic Assessment: Menkes Disease current marketed and Menkes Disease emerging therapies

• Menkes Disease Market Dynamics: Menkes Disease market drivers and Menkes Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Menkes Disease Unmet Needs, KOL’s views, Analyst’s views, Menkes Disease Market Access and Reimbursement

To know more about Menkes Disease companies working in the treatment market, visit @ Menkes Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Menkes Disease Market Report Introduction

2. Executive Summary for Menkes Disease

3. SWOT analysis of Menkes Disease

4. Menkes Disease Patient Share (%) Overview at a Glance

5. Menkes Disease Market Overview at a Glance

6. Menkes Disease Disease Background and Overview

7. Menkes Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Menkes Disease

9. Menkes Disease Current Treatment and Medical Practices

10. Menkes Disease Unmet Needs

11. Menkes Disease Emerging Therapies

12. Menkes Disease Market Outlook

13. Country-Wise Menkes Disease Market Analysis (2020–2034)

14. Menkes Disease Market Access and Reimbursement of Therapies

15. Menkes Disease Market Drivers

16. Menkes Disease Market Barriers

17. Menkes Disease Appendix

18. Menkes Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Menkes Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Cyprium Therapeutics and Sentynl Therapeutics, Cyprium Therapeutics, Inc.

The High-Grade Glioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“High-Grade Glioma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the High-Grade Glioma Market.

Some of the key takeaways from the High-Grade Glioma Pipeline Report:

• Companies across the globe are diligently working toward developing novel High-Grade Glioma treatment therapies with a considerable amount of success over the years.

• High-Grade Glioma companies working in the treatment market are Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others, are developing therapies for the High-Grade Glioma treatment

• Emerging High-Grade Glioma therapies in the different phases of clinical trials are- ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others are expected to have a significant impact on the High-Grade Glioma market in the coming years.

• In April 2025, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company advancing multimodal biological immunotherapies for cancer treatment, has announced the publication of a manuscript detailing the findings of a Phase 1b clinical trial. The study assessed the safety and tolerability of combining CAN-2409 with a prodrug (valacyclovir) and nivolumab, alongside standard treatments—neurosurgery, radiotherapy, and temozolomide—in patients newly diagnosed with high-grade glioma.

• In March 2025, Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a clinical-stage biotech company advancing next-generation targeted antitumor virotherapies, in collaboration with City of Hope—one of the leading U.S. cancer research and treatment institutions—has announced encouraging progress from a Phase 1 clinical trial. The study evaluates Calidi’s investigational agent CLD-101, a neural stem cell-based oncolytic virotherapy delivered intracerebrally. This marks the first trial assessing the safety and therapeutic potential of a multiple-dose regimen of CLD-101 in patients with recurrent high-grade glioma, one of the most aggressive and lethal brain cancers.

• In March 2025, Anova Enterprises, Inc. (Anova), a technology-driven CRO focused on expediting innovative treatments, has announced the enrollment of the first two patients in the Phase 1/2a clinical trial of DB107 for brain tumors. This multicenter, open-label study aims to evaluate whether DB107, when combined with the standard of care (SOC), offers clinical benefits to patients with newly diagnosed high-grade gliomas (HGG) compared to historical outcomes.

• In August 2024, Predictive diagnostics company Kiyatec revealed data demonstrating that its 3D Predict Glioma test enhances survival outcomes for patients with high-grade glioma (HGG) by accurately forecasting their response to chemotherapy. Published in Scientific Reports, the findings show that test responders experienced a median progression-free survival extension of 5.8 months and an overall survival increase of 7.6 months compared to non-responders. The study (NCT03561207) included 102 patients newly diagnosed with HGG, a cancer known for its poor prognosis.

• In May 2024, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company specializing in multimodal biological immunotherapies for cancer treatment, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to CAN-3110. This next-generation oncolytic viral immunotherapy is intended for treating recurrent high-grade glioma (rHGG). Glioblastoma (GBM), the most prevalent and aggressive type of high-grade glioma, remains a significant therapeutic challenge.

• In April 2024, Denovo Biopharma LLC (Denovo), a leader in utilizing precision medicine for developing innovative treatments, has announced that the California Institute for Regenerative Medicine (CIRM) has granted $11.8 million for the continued advancement of DB107. This is Denovo’s DGM7™ biomarker-guided late-stage gene therapy aimed at high-grade glioma (HGG), including glioblastoma (GBM), a type of malignant brain cancer. The grant has been awarded to Dr. Noriyuki Kasahara, MD, PhD, at the University of California San Francisco (UCSF), along with a team of researchers from California universities, to conduct a Phase 1/2 clinical trial evaluating DB107 in patients newly diagnosed with HGG.

High-Grade Glioma Overview

High-grade glioma (HGG) refers to a group of aggressive brain tumors that originate from glial cells, which provide support and protection for neurons. These tumors are classified as high-grade due to their rapid growth and tendency to invade surrounding brain tissue, making them difficult to treat. The most common type of HGG is glioblastoma multiforme (GBM), characterized by its heterogeneous cellular makeup and resistance to therapy. Symptoms of HGG can include headaches, seizures, cognitive changes, and neurological deficits, depending on the tumor’s location in the brain. Treatment typically involves a combination of surgery, radiation therapy, and chemotherapy, but the prognosis remains poor, with limited survival rates.

Get a Free Sample PDF Report to know more about High-Grade Glioma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/high-grade-glioma-pipeline-insight

Emerging High-Grade Glioma Drugs Under Different Phases of Clinical Development Include:

• ONC201: Chimerix

• BMX-001: BioMimetix

• OKN-007: Oblato, Inc.

• Lisavanbulin: Basilea Pharmaceutica

• Terameprocol: Erimos Pharmaceuticals

• Zotiraciclib: Adastra Pharmaceuticals/S*Bio

• PTC596: PTC Therapeutics

• OS2966: OncoSynergy

• CAN 3110: Candel Therap

• DSP 0390: Sumitomo Pharma Oncology, Inc.

• Terameprocol: Erimos Pharmaceuticals

• Lenvatinib: Eisai Inc.

• PVSRIPO: Istari Oncology, Inc.

• BMX-001: BioMimetix Pharma

High-Grade Glioma Route of Administration

High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Infusion

• Intradermal

• Intramuscular

• Intranasal

• Intravenous

• Oral

• Parenteral

• Subcutaneous

• Molecule Type

High-Grade Glioma Molecule Type

High-Grade Glioma Products have been categorized under various Molecule types, such as

• Gene therapies

• Small molecule

• Vaccines

• Polymers

• Peptides

• Monoclonal antibodies

• Product Type

High-Grade Glioma Pipeline Therapeutics Assessment

• High-Grade Glioma Assessment by Product Type

• High-Grade Glioma By Stage and Product Type

• High-Grade Glioma Assessment by Route of Administration

• High-Grade Glioma By Stage and Route of Administration

• High-Grade Glioma Assessment by Molecule Type

• High-Grade Glioma by Stage and Molecule Type

DelveInsight’s High-Grade Glioma Report covers around 150+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further High-Grade Glioma product details are provided in the report. Download the High-Grade Glioma pipeline report to learn more about the emerging High-Grade Glioma therapies

Some of the key companies in the High-Grade Glioma Therapeutics Market include:

Key companies developing therapies for High-Grade Glioma are – Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharmaceuticals, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, DelMar Pharmaceuticals, Bristol-Myers Squibb, Laminar Pharmaceuticals, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.

High-Grade Glioma Pipeline Analysis:

The High-Grade Glioma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of High-Grade Glioma with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for High-Grade Glioma Treatment.

• High-Grade Glioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• High-Grade Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the High-Grade Glioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about High-Grade Glioma drugs and therapies

High-Grade Glioma Pipeline Market Drivers

• Increasing the prevalence of High Grade Glioma, increase in the accessibility to more options for the treatment and diagnosis of a high-grade tumor are some of the important factors that are fueling the High-Grade Glioma Market.

High-Grade Glioma Pipeline Market Barriers

• However, high cost of the treatment, side effects associated with the treatment and other factors are creating obstacles in the High-Grade Glioma Market growth.

Scope of High-Grade Glioma Pipeline Drug Insight

• Coverage: Global

• Key High-Grade Glioma Companies: Chimerix, BioMimetix, Oblato, Inc., Basilea Pharmaceutica, Erimos Pharmaceuticals, Adastra Pharmaceuticals, PTC Therapeutics, Candel Therapeutics, OncoSynergy, Sumitomo Pharma Oncology, Inc., Erimos Pharmaceuticals, Eisai Inc., Istari Oncology, Inc., BioMimetix Pharma, and others

• Key High-Grade Glioma Therapies: ONC201, BMX-001, OKN-007, Lisavanbulin, Terameprocol, Zotiraciclib, PTC596, CAN-3110, OS2966, DSP 0390, Terameprocol, Lenvatinib, PVSRIPO, BMX-001, and others

• High-Grade Glioma Therapeutic Assessment: High-Grade Glioma current marketed and High-Grade Glioma emerging therapies

• High-Grade Glioma Market Dynamics: High-Grade Glioma market drivers and High-Grade Glioma market barriers

Request for Sample PDF Report for High-Grade Glioma Pipeline Assessment and clinical trials

Table of Contents

1. High-Grade Glioma Report Introduction

2. High-Grade Glioma Executive Summary

3. High-Grade Glioma Overview

4. High-Grade Glioma- Analytical Perspective In-depth Commercial Assessment

5. High-Grade Glioma Pipeline Therapeutics

6. High-Grade Glioma Late Stage Products (Phase II/III)

7. High-Grade Glioma Mid Stage Products (Phase II)

8. High-Grade Glioma Early Stage Products (Phase I)

9. High-Grade Glioma Preclinical Stage Products

10. High-Grade Glioma Therapeutics Assessment

11. High-Grade Glioma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. High-Grade Glioma Key Companies

14. High-Grade Glioma Key Products

15. High-Grade Glioma Unmet Needs

16 . High-Grade Glioma Market Drivers and Barriers

17. High-Grade Glioma Future Perspectives and Conclusion

18. High-Grade Glioma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: High-Grade Glioma Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by Delveinsight | Basilea Pharma, Erimos Pharma, Adastra Pharma, Chimerix, BioMimetix, Oblato, Inc.

“Scoliosis Therapeutics Market Report”

DelveInsight’s “Scoliosis Market Insight, Epidemiology and Market Forecast – 2032” report delivers an in-depth understanding of the scoliosis therapeutic landscape, including historical and forecasted epidemiology alongside current and emerging market trends across the 7MM (United States, EU4, United Kingdom, and Japan). The report covers the evolving treatment landscape, market share of individual therapies, and projects market size from 2019 to 2032. The scoliosis market in the 7MM is expected to grow significantly during the forecast period, with the US accounting for the largest market share due to its advanced healthcare infrastructure, favorable reimbursement policies, and rapid adoption of innovative treatment technologies.

Download the scoliosis market report to understand which factors are driving the scoliosis therapeutic market @ Scoliosis Market Trends.

Scoliosis, characterized by an abnormal sideways curvature of the spine resulting in S- or C-shaped deformity, affects people across all age groups but most commonly develops during adolescence. According to the epidemiological analysis provided in DelveInsight’s report, scoliosis impacts a substantial patient population across the 7MM, with varying prevalence rates by age, gender, and curve severity. The report segments the scoliosis patient population by age groups, curve magnitude, etiology (idiopathic, congenital, neuromuscular), and treatment-eligible cases, providing crucial data for healthcare planning and resource allocation. This detailed epidemiological understanding helps identify high-risk populations and develop targeted treatment strategies to address the specific needs of different scoliosis patient subgroups.

The majority of scoliosis cases are detected during adolescence, with the primary age of onset between 10 and 15 years. Furthermore, scoliosis is consistently more common in females than in males, and the likelihood of developing more severe curves is substantially higher in girls

Discover evolving trends in the scoliosis patient pool forecasts @ Scoliosis Epidemiology Analysis.

The current scoliosis treatment landscape encompasses a range of approaches tailored to the severity of the curve, patient age, growth status, and risk of progression. Non-surgical management includes observation, physical therapy, specialized exercise programs designed to strengthen spinal support muscles, and bracing therapy for moderate curves in skeletally immature patients. Surgical interventions such as spinal fusion and corrective procedures are necessary for severe scoliosis to stabilize the spine, prevent further progression, and address associated symptoms.

The scoliosis treatment pipeline shows robust activity, with several promising candidates in various stages of development targeting improved efficacy and reduced invasiveness. The competitive landscape is dynamic, with scoliosis companies such as Medicrea, Ellipse Technologies Inc, Apifix, Spinologics Inc, EOS imaging Inc, GE Healthcare, K2M Inc, Zimmer Biomet, Exponent Inc, Medtronic, NuVasive, and Bioventus LLC, among others, focusing on addressing key unmet needs, including early intervention options, non-fusion technologies, and improved long-term outcomes.

DelveInsight’s analysis further highlights the scoliosis pipeline development activities, collaborations, acquisitions, and licensing agreements that are shaping the future of scoliosis treatment. The report also examines the reimbursement scenario across different regions, providing insights into market access challenges and opportunities for new entrants.

Recent years have witnessed significant advancements in scoliosis management, with emphasis on developing less invasive surgical techniques, innovative bracing technologies, and novel approaches to spinal correction. In February 2024, Momentum Health Inc. received FDA 510K clearance for its AI-enabled mobile application, Momentum Spine, designed for monitoring scoliosis. The app uses 3D imaging to reconstruct a model of the torso and provides real-time asymmetry measurements.

In February 2025, a study compared a digital care group, where patients received exercise supervision via an app, with a usual care group for adolescents with idiopathic scoliosis (AIS). Findings indicated that the digital care group experienced significantly greater improvement in Cobb angle reduction. The digital system provided personalized guidance, leading to increased adherence to treatment and improved outcomes.

Furthermore, in April 2025, OrthoPediatrics Corp. (NASDAQ: KIDS) expanded its scoliosis portfolio with the launch of the VerteGlide System, a guided growth technology developed for children with Early Onset Scoliosis. This new system is designed to address the unique needs of pediatric patients.

Discover recent advancements in the scoliosis treatment landscape @ Scoliosis Recent Developments.

The integration of 3D imaging, computer-assisted navigation systems, and personalized treatment planning has substantially improved scoliosis diagnostic accuracy and treatment outcomes. Additionally, growth-modulation devices that preserve spinal motion compared to traditional fusion techniques represent promising alternatives for growing children. These technological innovations are transforming the scoliosis treatment landscape and driving market growth across the 7MM.

Looking ahead, the scoliosis market is expected to undergo significant transformation. The increasing adoption of school screening programs for early detection, growing patient awareness, and rising healthcare expenditure will further contribute to market expansion. Additionally, the shift toward personalized treatment approaches based on patient-specific factors such as curve pattern, skeletal maturity, and risk of progression is expected to optimize clinical outcomes and drive innovation in this therapeutic area.

The comprehensive insights provided in DelveInsight’s report offer valuable perspectives for healthcare stakeholders to understand the evolving scoliosis treatment paradigm and effectively position their strategies in this dynamic market landscape. With continued innovation and increasing focus on patient-centered care, the scoliosis market presents significant opportunities for growth and advancement in addressing this common spinal condition affecting millions worldwide.

Table of Contents

1. Key Insights

2. Executive Summary of Scoliosis

3. Competitive Intelligence Analysis for Scoliosis

4. Scoliosis: Market Overview at a Glance

5. Scoliosis: Disease Background and Overview

6. Scoliosis Patient Journey

7. Scoliosis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Scoliosis Unmet Needs

10. Key Endpoints of Scoliosis Treatment

11. Scoliosis Marketed Products

12. Scoliosis Emerging Therapies

13. Scoliosis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Scoliosis

17. KOL Views

18. Scoliosis Market Drivers

19. Scoliosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports

Idiopathic Scoliosis Pipeline Insight

Idiopathic Scoliosis pipeline insight provides comprehensive insights about the idiopathic scoliosis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the idiopathic scoliosis companies, including OrthoPediatrics Corp. (NASDAQ: KIDS), ApiFix Ltd., Zimmer Biomet (NYSE: ZBH), Globus Medical, Auctus Surgical, Medtronic (NYSE: MDT), SpineGuide Technologies, Boston Orthotics & Prosthetics, Aspen Medical Products, Spinal Technology, Inc., Optec USA, Inc., Wilmington Orthotics & Prosthetics, Inc., Lawall Prosthetics and Orthotics, Horton’s Orthotics & Prosthetics, Ortholutions GmbH & Co. KG, Ossur Hf, Charleston Bending Brace, UNYQ, Pro-Tech Orthopedics, Johnson & Johnson (NYSE: JNJ), Orthofix Holdings Inc. (NASDAQ: OFIX), NuVasive Inc. (NASDAQ: NUVA), Cascade Orthotics, Ottobock, and DM Orthotics Ltd., among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Scoliosis Therapeutics Market Poised for Substantial Growth by 2032, Driven by a Dynamic Competitive Landscape and FDA Approvals | DelveInsight

DelveInsight’s “Herpes Simplex Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Herpes Simplex, historical and forecasted epidemiology as well as the Herpes Simplex market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Herpes Simplex market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Herpes Simplex Market Forecast

Some of the key facts of the Herpes Simplex Market Report:

• The Herpes Simplex market size was valued ~USD 3,159 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In September 2024, GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial for its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, failed to achieve its primary efficacy endpoint. This conclusion was drawn from an analysis of the primary objective data from the Phase II segment of the trial. Designed to offer a new therapeutic option for HSV, GSK3943104 will not be advanced to Phase III studies following the trial results.

• As per DelveInsight’s analysis, the United States held the largest market share for Herpes Simplex in the 7MM, with a market size of USD 1,590 million in 2023.

• In 2023, Germany led the EU4 with the largest market size for Herpes Simplex at USD 320 million, followed by the UK at USD 282 million, while Spain had the smallest market size at USD 173 million.

• According to estimates, Japan’s market size for Herpes Simplex was around USD 349 million in 2023, with expectations of growth throughout the forecast period.

• In 2023, the total diagnosed cases of Herpes Simplex in the 7MM were approximately 13,038 thousand. These cases are projected to rise over the study period from 2020 to 2034.

• According to DelveInsight’s estimates, the United States accounted for approximately 38% of the total diagnosed prevalent cases of Herpes Simplex in the 7MM in 2023.

• In 2023, gender-specific cases of Herpes Simplex in the EU4 and the UK were roughly 45% male and 55% female. These cases are expected to decline over time.

• In 2023, Germany had the highest number of prevalent Herpes Simplex cases among the EU4 and the UK, followed by the UK, which recorded approximately 1,511 thousand cases.

• In 2023, recurrent herpes simplex cases in Japan showed that HSV-2 accounted for more than 67%, while HSV-1 made up 33%.

• Key Herpes Simplex Companies: Labo’Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others

• Key Herpes Simplex Therapies: 2LHERP®, Pritelivir, GSK3943104, mRNA-1608, AMENALIEF (amenamevir), SITAVIG (acyclovir), famciclovir, ASP2151, BTL TML HSV, and others

• The Herpes Simplex market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Herpes Simplex pipeline products will significantly revolutionize the Herpes Simplex market dynamics.

Herpes Simplex Overview

Herpes Simplex is a viral infection caused by the herpes simplex virus (HSV). It comes in two forms: HSV-1, which primarily causes oral herpes (cold sores), and HSV-2, which typically causes genital herpes. Both types can cause sores or blisters at the infection site and are transmitted through direct contact with the infected areas or bodily fluids. While there is no cure for herpes, antiviral treatments can help manage symptoms and reduce the risk of transmission. The virus can remain dormant in the body and reactivate periodically, causing recurrent outbreaks.

Get a Free sample for the Herpes Simplex Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/herpes-simplex-market

Herpes Simplex Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Herpes Simplex Epidemiology Segmentation:

The Herpes Simplex market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Seroprevalence of HSV in the 7MM

• Total Symptomatic Cases of HSV in the 7MM

• Total Diagnosed Cases of HSV in the 7MM

• Gender-specific Diagnosed Cases of HSV in the 7MM

• Total Recurrent Cases of HSV in the 7MM

Download the report to understand which factors are driving Herpes Simplex epidemiology trends @ Herpes Simplex Epidemiology Forecast

Herpes Simplex Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Herpes Simplex market or expected to get launched during the study period. The analysis covers Herpes Simplex market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Herpes Simplex Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Herpes Simplex Therapies and Key Companies

• 2LHERP®: Labo’Life

• Pritelivir: AiCuris Anti-infective Cures AG

• GSK3943104: GlaxoSmithKline

• mRNA-1608: ModernaTX, Inc.

• AMENALIEF (amenamevir): Maruho Co., Ltd.

• SITAVIG (acyclovir): Bioalliance Pharma/Vectans Pharma

• famciclovir: Novartis

• ASP2151: Maruho Co., Ltd.

• BTL TML HSV: Beech Tree Labs, Inc.

Discover more about therapies set to grab major Herpes Simplex market share @ Herpes Simplex Treatment Landscape

Herpes Simplex Market Strengths

• The increase in healthcare expenditure in developing countries has increased access to healthcare services, including HSV treatment. This has increased the access to healthcare and surged the demand for herpes simplex virus treatment.

• The chronic and recurrent nature of HSV infections creates a sustained need for ongoing care and treatment options in the market.

Herpes Simplex Market Opportunities

• Collaboration between research institutes and healthcare sectors will immensely boost the market and its potential to make better curative therapies than existing palliative care.

• Raising public awareness for herpes simplex infections can result in an earlier diagnosis and initiation of therapy ultimately boosting the financial state.

Scope of the Herpes Simplex Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Herpes Simplex Companies: Labo’Life, AiCuris Anti-infective Cures AG, GlaxoSmithKline, ModernaTX, Inc., Maruho Co., Ltd., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co., Ltd., Beech Tree Labs, Inc., and others

• Key Herpes Simplex Therapies: 2LHERP®, Pritelivir, GSK3943104, mRNA-1608, AMENALIEF (amenamevir), SITAVIG (acyclovir), famciclovir, ASP2151, BTL TML HSV, and others

• Herpes Simplex Therapeutic Assessment: Herpes Simplex current marketed and Herpes Simplex emerging therapies

• Herpes Simplex Market Dynamics: Herpes Simplex market drivers and Herpes Simplex market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Herpes Simplex Unmet Needs, KOL’s views, Analyst’s views, Herpes Simplex Market Access and Reimbursement

To know more about Herpes Simplex companies working in the treatment market, visit @ Herpes Simplex Clinical Trials and Therapeutic Assessment

Table of Contents

1. Herpes Simplex Market Report Introduction

2. Executive Summary for Herpes Simplex

3. SWOT analysis of Herpes Simplex

4. Herpes Simplex Patient Share (%) Overview at a Glance

5. Herpes Simplex Market Overview at a Glance

6. Herpes Simplex Disease Background and Overview

7. Herpes Simplex Epidemiology and Patient Population

8. Country-Specific Patient Population of Herpes Simplex

9. Herpes Simplex Current Treatment and Medical Practices

10. Herpes Simplex Unmet Needs

11. Herpes Simplex Emerging Therapies

12. Herpes Simplex Market Outlook

13. Country-Wise Herpes Simplex Market Analysis (2020–2034)

14. Herpes Simplex Market Access and Reimbursement of Therapies

15. Herpes Simplex Market Drivers

16. Herpes Simplex Market Barriers

17. Herpes Simplex Appendix

18. Herpes Simplex Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Herpes Simplex Market to Expand Significantly by 203, States DelveInsight Report | GlaxoSmithKline, ModernaTX, Maruho Co., Bioalliance Pharma/Vectans Pharma, Novartis, Maruho Co